Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 446

1.

Partial loss of function of colony-stimulating factor 1 receptor in a patient with white matter abnormalities.

Konno T, Miura T, Harriott AM, Mezaki N, Edwards ES, Rademakers R, Ross OA, Meschia JF, Ikeuchi T, Wszolek ZK.

Eur J Neurol. 2018 Mar 6. doi: 10.1111/ene.13611. [Epub ahead of print]

PMID:
29509319
2.

PINK1 Phosphorylates MIC60/Mitofilin to Control Structural Plasticity of Mitochondrial Crista Junctions.

Tsai PI, Lin CH, Hsieh CH, Papakyrikos AM, Kim MJ, Napolioni V, Schoor C, Couthouis J, Wu RM, Wszolek ZK, Winter D, Greicius MD, Ross OA, Wang X.

Mol Cell. 2018 Mar 1;69(5):744-756.e6. doi: 10.1016/j.molcel.2018.01.026. Epub 2018 Feb 15.

PMID:
29456190
3.

The effect of LRRK2 mutations on the cholinergic system in manifest and premanifest stages of Parkinson's disease: a cross-sectional PET study.

Liu SY, Wile DJ, Fu JF, Valerio J, Shahinfard E, McCormick S, Mabrouk R, Vafai N, McKenzie J, Neilson N, Perez-Soriano A, Arena JE, Cherkasova M, Chan P, Zhang J, Zabetian CP, Aasly JO, Wszolek ZK, McKeown MJ, Adam MJ, Ruth TJ, Schulzer M, Sossi V, Stoessl AJ.

Lancet Neurol. 2018 Apr;17(4):309-316. doi: 10.1016/S1474-4422(18)30032-2. Epub 2018 Feb 16.

PMID:
29456161
4.

Multiple system atrophy and apolipoprotein E.

Ogaki K, Martens YA, Heckman MG, Koga S, Labbé C, Lorenzo-Betancor O, Wernick AI, Walton RL, Soto AI, Vargas ER, Nielsen HM, Fujioka S, Kanekiyo T, Uitti RJ, van Gerpen JA, Cheshire WP, Wszolek ZK, Low PA, Singer W, Dickson DW, Bu G, Ross OA.

Mov Disord. 2018 Apr;33(4):647-650. doi: 10.1002/mds.27297. Epub 2018 Feb 14.

PMID:
29442376
5.

Daytime sleepiness in dementia with Lewy bodies is associated with neuronal depletion of the nucleus basalis of Meynert.

Kasanuki K, Ferman TJ, Murray ME, Heckman MG, Pedraza O, Hanna Al-Shaikh FS, Mishima T, Diehl NN, van Gerpen JA, Uitti RJ, Wszolek ZK, Graff-Radford NR, Dickson DW.

Parkinsonism Relat Disord. 2018 Feb 3. pii: S1353-8020(18)30039-7. doi: 10.1016/j.parkreldis.2018.02.003. [Epub ahead of print]

PMID:
29429645
6.

Comparison of clinical features among Parkinson's disease subtypes: A large retrospective study in a single center.

Konno T, Deutschländer A, Heckman MG, Ossi M, Vargas ER, Strongosky AJ, van Gerpen JA, Uitti RJ, Ross OA, Wszolek ZK.

J Neurol Sci. 2018 Mar 15;386:39-45. doi: 10.1016/j.jns.2018.01.013. Epub 2018 Jan 11.

PMID:
29406964
7.

Diaphragmatic Pacemaker for Perry Syndrome.

Konno T, Wszolek ZK.

Mayo Clin Proc. 2018 Feb;93(2):263. doi: 10.1016/j.mayocp.2017.11.014. No abstract available.

PMID:
29406204
8.

Letter to the Readership of the Polish Journal of Neurology and Neurosurgery.

Wszolek ZK, Slawek J.

Neurol Neurochir Pol. 2018 Mar;52(2):123. doi: 10.1016/j.pjnns.2018.01.002. Epub 2018 Feb 1. No abstract available.

PMID:
29395117
9.

Slowly progressive dementia caused by MAPT R406W mutations: longitudinal report on a new kindred and systematic review.

Ygland E, van Westen D, Englund E, Rademakers R, Wszolek ZK, Nilsson K, Nilsson C, Landqvist Waldö M, Alafuzoff I, Hansson O, Gustafson L, Puschmann A.

Alzheimers Res Ther. 2018 Jan 9;10(1):2. doi: 10.1186/s13195-017-0330-2.

10.

So long, and thanks for all the fish.

Wszolek ZK, Pfeiffer RF.

Parkinsonism Relat Disord. 2018 Jan;46:1. doi: 10.1016/j.parkreldis.2017.12.027. No abstract available.

PMID:
29295733
11.

Restless legs syndrome and nocturnal leg cramps: a review and guide to diagnosis and treatment.

Tipton PW, Wszołek ZK.

Pol Arch Intern Med. 2017 Dec 22;127(12):865-872. doi: 10.20452/pamw.4148. Epub 2017 Nov 9.

12.

The limbic and neocortical contribution of α-synuclein, tau, and amyloid β to disease duration in dementia with Lewy bodies.

Ferman TJ, Aoki N, Crook JE, Murray ME, Graff-Radford NR, van Gerpen JA, Uitti RJ, Wszolek ZK, Graff-Radford J, Pedraza O, Kantarci K, Boeve BF, Dickson DW.

Alzheimers Dement. 2018 Mar;14(3):330-339. doi: 10.1016/j.jalz.2017.09.014. Epub 2017 Oct 31.

PMID:
29100980
13.

Establishing diagnostic criteria for Perry syndrome.

Mishima T, Fujioka S, Tomiyama H, Yabe I, Kurisaki R, Fujii N, Neshige R, Ross OA, Farrer MJ, Dickson DW, Wszolek ZK, Hattori N, Tsuboi Y.

J Neurol Neurosurg Psychiatry. 2018 May;89(5):482-487. doi: 10.1136/jnnp-2017-316864. Epub 2017 Oct 31.

14.

Cognitive impairment in progressive supranuclear palsy is associated with tau burden.

Koga S, Parks A, Kasanuki K, Sanchez-Contreras M, Baker MC, Josephs KA, Ahlskog JE, Uitti RJ, Graff-Radford N, van Gerpen JA, Wszolek ZK, Rademakers R, Dickson DW.

Mov Disord. 2017 Dec;32(12):1772-1779. doi: 10.1002/mds.27198. Epub 2017 Oct 30.

PMID:
29082658
15.

Progranulin-mediated deficiency of cathepsin D results in FTD and NCL-like phenotypes in neurons derived from FTD patients.

Valdez C, Wong YC, Schwake M, Bu G, Wszolek ZK, Krainc D.

Hum Mol Genet. 2017 Dec 15;26(24):4861-4872. doi: 10.1093/hmg/ddx364.

PMID:
29036611
16.

CSF1R-Related Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia.

Sundal C, Wszolek ZK.

In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2018.
2012 Aug 30 [updated 2017 Oct 5].

17.

Diagnostic criteria for adult-onset leukoencephalopathy with axonal spheroids and pigmented glia due to CSF1R mutation.

Konno T, Yoshida K, Mizuta I, Mizuno T, Kawarai T, Tada M, Nozaki H, Ikeda SI, Onodera O, Wszolek ZK, Ikeuchi T.

Eur J Neurol. 2018 Jan;25(1):142-147. doi: 10.1111/ene.13464. Epub 2017 Oct 19.

PMID:
28921817
18.

DCTN1 variation in pathologically-confirmed PSP and CBD tauopathy.

Sanchez-Contreras M, Soto AI, Walton RL, Wszolek ZK, Dickson DW, Ross OA, Rademakers R.

Parkinsonism Relat Disord. 2017 Nov;44:151-153. doi: 10.1016/j.parkreldis.2017.08.027. Epub 2017 Aug 30. No abstract available.

PMID:
28867162
19.

Brain calcification in a CSF1R mutation carrier precedes white matter degeneration.

Konno T, Broderick DF, Wszolek ZK.

Mov Disord. 2017 Oct;32(10):1493-1495. doi: 10.1002/mds.27130. Epub 2017 Aug 26. No abstract available.

PMID:
28843019
20.

TIA1 Mutations in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Promote Phase Separation and Alter Stress Granule Dynamics.

Mackenzie IR, Nicholson AM, Sarkar M, Messing J, Purice MD, Pottier C, Annu K, Baker M, Perkerson RB, Kurti A, Matchett BJ, Mittag T, Temirov J, Hsiung GR, Krieger C, Murray ME, Kato M, Fryer JD, Petrucelli L, Zinman L, Weintraub S, Mesulam M, Keith J, Zivkovic SA, Hirsch-Reinshagen V, Roos RP, Züchner S, Graff-Radford NR, Petersen RC, Caselli RJ, Wszolek ZK, Finger E, Lippa C, Lacomis D, Stewart H, Dickson DW, Kim HJ, Rogaeva E, Bigio E, Boylan KB, Taylor JP, Rademakers R.

Neuron. 2017 Aug 16;95(4):808-816.e9. doi: 10.1016/j.neuron.2017.07.025.

PMID:
28817800
21.

Atypical parkinsonian syndromes: a general neurologist's perspective.

Deutschländer AB, Ross OA, Dickson DW, Wszolek ZK.

Eur J Neurol. 2018 Jan;25(1):41-58. doi: 10.1111/ene.13412. Epub 2017 Sep 28. Review.

PMID:
28803444
22.

VPS35-Related Parkinson Disease.

Deutschländer A, Ross OA, Wszolek ZK.

In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2018.
2017 Aug 10.

23.

Perry Syndrome: A Distinctive Type of TDP-43 Proteinopathy.

Mishima T, Koga S, Lin WL, Kasanuki K, Castanedes-Casey M, Wszolek ZK, Oh SJ, Tsuboi Y, Dickson DW.

J Neuropathol Exp Neurol. 2017 Aug 1;76(8):676-682. doi: 10.1093/jnen/nlx049.

PMID:
28789478
24.

Reduced orexin immunoreactivity in Perry syndrome and multiple system atrophy.

Mishima T, Kasanuki K, Koga S, Castanedes-Casey M, Wszolek ZK, Tsuboi Y, Dickson DW.

Parkinsonism Relat Disord. 2017 Sep;42:85-89. doi: 10.1016/j.parkreldis.2017.06.003. Epub 2017 Jun 12.

PMID:
28651750
25.

DCTN1-related neurodegeneration: Perry syndrome and beyond.

Konno T, Ross OA, Teive HAG, Sławek J, Dickson DW, Wszolek ZK.

Parkinsonism Relat Disord. 2017 Aug;41:14-24. doi: 10.1016/j.parkreldis.2017.06.004. Epub 2017 Jun 12. Review.

PMID:
28625595
26.

APOE ε4/ε4 diminishes neurotrophic function of human iPSC-derived astrocytes.

Zhao J, Davis MD, Martens YA, Shinohara M, Graff-Radford NR, Younkin SG, Wszolek ZK, Kanekiyo T, Bu G.

Hum Mol Genet. 2017 Jul 15;26(14):2690-2700. doi: 10.1093/hmg/ddx155.

PMID:
28444230
27.

The PINK1 p.I368N mutation affects protein stability and ubiquitin kinase activity.

Ando M, Fiesel FC, Hudec R, Caulfield TR, Ogaki K, Górka-Skoczylas P, Koziorowski D, Friedman A, Chen L, Dawson VL, Dawson TM, Bu G, Ross OA, Wszolek ZK, Springer W.

Mol Neurodegener. 2017 Apr 24;12(1):32. doi: 10.1186/s13024-017-0174-z.

28.

Reply: Heterozygous PINK1 p.G411S in rapid eye movement sleep behaviour disorder.

Puschmann A, Fiesel FC, Caulfield TR, Hudec R, Ando M, Truban D, Hou X, Ogaki K, Heckman MG, James ED, Swanberg M, Jimenez-Ferrer I, Hansson O, Opala G, Siuda J, Boczarska-Jedynak M, Friedman A, Koziorowski D, Rudzinska-Bar M, Aasly JO, Lynch T, Mellick GD, Mohan M, Silburn PA, Sanotsky Y, Vilariño-Güell C, Farrer MJ, Chen L, Dawson VL, Dawson TM, Wszolek ZK, Ross OA, Springer W.

Brain. 2017 Jun 1;140(6):e33. doi: 10.1093/brain/awx077. No abstract available.

PMID:
28379295
29.

Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies.

Wile DJ, Agarwal PA, Schulzer M, Mak E, Dinelle K, Shahinfard E, Vafai N, Hasegawa K, Zhang J, McKenzie J, Neilson N, Strongosky A, Uitti RJ, Guttman M, Zabetian CP, Ding YS, Adam M, Aasly J, Wszolek ZK, Farrer M, Sossi V, Stoessl AJ.

Lancet Neurol. 2017 May;16(5):351-359. doi: 10.1016/S1474-4422(17)30056-X. Epub 2017 Mar 20.

PMID:
28336296
30.

Occurrence of Crohn's disease with Parkinson's disease.

Fujioka S, Curry SE, Kennelly KD, Tacik P, Heckman MG, Tsuboi Y, Strongosky AJ, van Gerpen JA, Uitti RJ, Ross OA, Ikezu T, Wszolek ZK.

Parkinsonism Relat Disord. 2017 Apr;37:116-117. doi: 10.1016/j.parkreldis.2017.01.013. Epub 2017 Feb 10.

PMID:
28215729
31.

Drawing analysis in the assessment of patients with neurodegenerative diseases.

Sitek EJ, Narożańska E, Konieczna S, Brockhuis B, Wieczorek D, Wszolek ZK, Sławek J.

Neurology. 2017 Jan 10;88(2):218-219. doi: 10.1212/WNL.0000000000003496. No abstract available.

32.

Distribution and characteristics of transactive response DNA binding protein 43 kDa pathology in progressive supranuclear palsy.

Koga S, Sanchez-Contreras M, Josephs KA, Uitti RJ, Graff-Radford N, van Gerpen JA, Cheshire WP, Wszolek ZK, Rademakers R, Dickson DW.

Mov Disord. 2017 Feb;32(2):246-255. doi: 10.1002/mds.26809. Epub 2016 Dec 23.

PMID:
28009087
33.

Spinocerebellar ataxia 15: A phenotypic review and expansion.

Tipton PW, Guthrie K, Strongosky A, Reimer R, Wszolek ZK.

Neurol Neurochir Pol. 2017 Jan - Feb;51(1):86-91. doi: 10.1016/j.pjnns.2016.10.006. Epub 2016 Nov 10. Review.

34.

Profile of cognitive impairment and underlying pathology in multiple system atrophy.

Koga S, Parks A, Uitti RJ, van Gerpen JA, Cheshire WP, Wszolek ZK, Dickson DW.

Mov Disord. 2017 Mar;32(3):405-413. doi: 10.1002/mds.26874. Epub 2016 Nov 15.

35.

Clinicopathologic heterogeneity in frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17) due to microtubule-associated protein tau (MAPT) p.P301L mutation, including a patient with globular glial tauopathy.

Tacik P, Sanchez-Contreras M, DeTure M, Murray ME, Rademakers R, Ross OA, Wszolek ZK, Parisi JE, Knopman DS, Petersen RC, Dickson DW.

Neuropathol Appl Neurobiol. 2017 Apr;43(3):200-214. doi: 10.1111/nan.12367. Epub 2017 Mar 8.

36.

Assessment of Olfactory Function in MAPT-Associated Neurodegenerative Disease Reveals Odor-Identification Irreproducibility as a Non-Disease-Specific, General Characteristic of Olfactory Dysfunction.

Markopoulou K, Chase BA, Robowski P, Strongosky A, Narożańska E, Sitek EJ, Berdynski M, Barcikowska M, Baker MC, Rademakers R, Sławek J, Klein C, Hückelheim K, Kasten M, Wszolek ZK.

PLoS One. 2016 Nov 17;11(11):e0165112. doi: 10.1371/journal.pone.0165112. eCollection 2016.

37.

Cerebral peduncle angle: Unreliable in differentiating progressive supranuclear palsy from other neurodegenerative diseases.

Tipton PW, Konno T, Broderick DF, Dickson DW, Wszolek ZK.

Parkinsonism Relat Disord. 2016 Nov;32:31-35. doi: 10.1016/j.parkreldis.2016.08.009. Epub 2016 Aug 11.

38.

Heterozygous PINK1 p.G411S increases risk of Parkinson's disease via a dominant-negative mechanism.

Puschmann A, Fiesel FC, Caulfield TR, Hudec R, Ando M, Truban D, Hou X, Ogaki K, Heckman MG, James ED, Swanberg M, Jimenez-Ferrer I, Hansson O, Opala G, Siuda J, Boczarska-Jedynak M, Friedman A, Koziorowski D, Aasly JO, Lynch T, Mellick GD, Mohan M, Silburn PA, Sanotsky Y, Vilariño-Güell C, Farrer MJ, Chen L, Dawson VL, Dawson TM, Wszolek ZK, Ross OA, Springer W.

Brain. 2017 Jan;140(1):98-117. doi: 10.1093/brain/aww261. Epub 2016 Nov 2.

39.

Genome-wide association study in essential tremor identifies three new loci.

Müller SH, Girard SL, Hopfner F, Merner ND, Bourassa CV, Lorenz D, Clark LN, Tittmann L, Soto-Ortolaza AI, Klebe S, Hallett M, Schneider SA, Hodgkinson CA, Lieb W, Wszolek ZK, Pendziwiat M, Lorenzo-Betancor O, Poewe W, Ortega-Cubero S, Seppi K, Rajput A, Hussl A, Rajput AH, Berg D, Dion PA, Wurster I, Shulman JM, Srulijes K, Haubenberger D, Pastor P, Vilariño-Güell C, Postuma RB, Bernard G, Ladwig KH, Dupré N, Jankovic J, Strauch K, Panisset M, Winkelmann J, Testa CM, Reischl E, Zeuner KE, Ross OA, Arzberger T, Chouinard S, Deuschl G, Louis ED, Kuhlenbäumer G, Rouleau GA.

Brain. 2016 Dec;139(Pt 12):3163-3169. Epub 2016 Oct 20.

40.

Study of LRRK2 variation in tauopathy: Progressive supranuclear palsy and corticobasal degeneration.

Sanchez-Contreras M, Heckman MG, Tacik P, Diehl N, Brown PH, Soto-Ortolaza AI, Christopher EA, Walton RL, Ross OA, Golbe LI, Graff-Radford N, Wszolek ZK, Dickson DW, Rademakers R.

Mov Disord. 2017 Jan;32(1):115-123. doi: 10.1002/mds.26815. Epub 2016 Oct 6.

41.

Clinical and genetic characterization of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia associated with CSF1R mutation.

Konno T, Yoshida K, Mizuno T, Kawarai T, Tada M, Nozaki H, Ikeda SI, Nishizawa M, Onodera O, Wszolek ZK, Ikeuchi T.

Eur J Neurol. 2017 Jan;24(1):37-45. doi: 10.1111/ene.13125. Epub 2016 Sep 29.

42.

Primary familial brain calcification in the 'IBGC2' kindred: All linkage roads lead to SLC20A2.

Grütz K, Volpato CB, Domingo A, Alvarez-Fischer D, Gebert U, Schifferle G, Buffone E, Wszolek ZK, Rademakers R, Ferbert A, Hicks AA, Klein C, Pramstaller PP, Westenberger A.

Mov Disord. 2016 Dec;31(12):1901-1904. doi: 10.1002/mds.26768. Epub 2016 Sep 27.

PMID:
27671522
43.

Diagnostic Value of Brain Calcifications in Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia.

Konno T, Broderick DF, Mezaki N, Isami A, Kaneda D, Tashiro Y, Tokutake T, Keegan BM, Woodruff BK, Miura T, Nozaki H, Nishizawa M, Onodera O, Wszolek ZK, Ikeuchi T.

AJNR Am J Neuroradiol. 2017 Jan;38(1):77-83. doi: 10.3174/ajnr.A4938. Epub 2016 Sep 15.

44.

Deep brain stimulation for levodopa-refractory benign tremulous parkinsonism.

Konno T, Ross OA, Wharen RE, Uitti RJ, Wszolek ZK.

Neurol Neurochir Pol. 2016;50(5):383-6. doi: 10.1016/j.pjnns.2016.05.008. Epub 2016 Jun 24.

45.

Association of GBA Mutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease.

Davis MY, Johnson CO, Leverenz JB, Weintraub D, Trojanowski JQ, Chen-Plotkin A, Van Deerlin VM, Quinn JF, Chung KA, Peterson-Hiller AL, Rosenthal LS, Dawson TM, Albert MS, Goldman JG, Stebbins GT, Bernard B, Wszolek ZK, Ross OA, Dickson DW, Eidelberg D, Mattis PJ, Niethammer M, Yearout D, Hu SC, Cholerton BA, Smith M, Mata IF, Montine TJ, Edwards KL, Zabetian CP.

JAMA Neurol. 2016 Oct 1;73(10):1217-1224. doi: 10.1001/jamaneurol.2016.2245.

46.

FTDP-17 with Pick body-like inclusions associated with a novel tau mutation, p.E372G.

Tacik P, DeTure MA, Carlomagno Y, Lin WL, Murray ME, Baker MC, Josephs KA, Boeve BF, Wszolek ZK, Graff-Radford NR, Parisi JE, Petrucelli L, Rademakers R, Isaacson RS, Heilman KM, Petersen RC, Dickson DW, Kouri N.

Brain Pathol. 2017 Sep;27(5):612-626. doi: 10.1111/bpa.12428. Epub 2016 Oct 5.

PMID:
27529406
47.

LRRK2 variation and dementia with Lewy bodies.

Heckman MG, Soto-Ortolaza AI, Contreras MYS, Murray ME, Pedraza O, Diehl NN, Walton R, Labbé C, Lorenzo-Betancor O, Uitti RJ, van Gerpen J, Ertekin-Taner N, Smith GE, Kantarci K, Savica R, Jones DT, Graff-Radford J, Knopman DS, Lowe VJ, Jack CR Jr, Petersen RC, Parisi JE, Rademakers R, Wszolek ZK, Graff-Radford NR, Ferman TJ, Dickson DW, Boeve BF, Ross OA.

Parkinsonism Relat Disord. 2016 Oct;31:98-103. doi: 10.1016/j.parkreldis.2016.07.015. Epub 2016 Jul 29.

48.

Genetics of Parkinson's disease: a review of SNCA and LRRK2.

Konno T, Siuda J, Wszolek ZK.

Wiad Lek. 2016;69(3 Pt 1):328-32. Review.

PMID:
27486710
49.

RAB39B gene mutations are not a common cause of Parkinson's disease or dementia with Lewy bodies.

Hodges K, Brewer SS, Labbé C, Soto-Ortolaza AI, Walton RL, Strongosky AJ, Uitti RJ, van Gerpen JA, Ertekin-Taner N, Kantarci K, Lowe VJ, Parisi JE, Savica R, Graff-Radford J, Jones DT, Knopman DS, Petersen RC, Murray ME, Graff-Radford NR, Ferman TJ, Dickson DW, Wszolek ZK, Boeve BF, Ross OA, Lorenzo-Betancor O.

Neurobiol Aging. 2016 Sep;45:107-108. doi: 10.1016/j.neurobiolaging.2016.03.021. Epub 2016 Mar 24.

PMID:
27459931
50.

TREM2 p.R47H substitution is not associated with dementia with Lewy bodies.

Walton RL, Soto-Ortolaza AI, Murray ME, Lorenzo-Betancor O, Ogaki K, Heckman MG, Rayaprolu S, Rademakers R, Ertekin-Taner N, Uitti RJ, van Gerpen JA, Wszolek ZK, Smith GE, Kantarci K, Lowe VJ, Parisi JE, Jones DT, Savica R, Graff-Radford J, Knopman DS, Petersen RC, Graff-Radford NR, Ferman TJ, Dickson DW, Boeve BF, Ross OA, Labbé C.

Neurol Genet. 2016 Jul 14;2(4):e85. doi: 10.1212/NXG.0000000000000085. eCollection 2016 Aug.

Supplemental Content

Loading ...
Support Center